Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06266572 · ClinicalTrials.gov registry record · Phase 1
Overcoming Stigma and Improving Outcomes for SUDs Through Education, Engagement, and Empowerment
A Phase 1 study, sponsored by Center for Social Innovation, Massachusetts.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT06266572: Completed Phase 1 study, sponsored by Center for Social Innovation, Massachusetts.
NCT06266572 is a Phase 1 study that has completed, run by Center for Social Innovation, Massachusetts. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06266572, a Phase 1 study, has completed, sponsored by Center for Social Innovation, Massachusetts.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
C4 Innovations (C4) and partners at Yale University (Yale) and the West Haven VA Medical Center (WHVA) proposed to develop and test OASIS (Overcoming and Addressing Stigma in Substance Use Disorders), a web-based educational platform for primary care clinicians and individuals with Opioid Use Disorder. The major aims of the study were to: 1. Develop a prototype of OASIS for patients with Opioid Use Disorder (OUD) and primary care clinicians; conduct usability testing. 2. Pilot OASIS with a small sample of individuals with untreated OUD and their clinicians to determine feasibility, acceptability, and preliminary product effectiveness for a Phase II effectiveness trial. After development of the prototype, the C4-Yale-WHVA team planned to test OASIS with patients (N = 30) and clinicians (N = 5) using validated measures and qualitative interviews to assess usability, satisfaction, knowledge, empowerment, and stigma.
Primary Outcome
Description: A 20-item scale assessing stigma in health care providers, rated on a 5 point likert scale from Strongly Disagree (1) to Strongly Agree (5).
Interventions
- BEHAVIORAL Overcoming and Addressing Stigma in Substance Use Disorders (OASIS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2023-09-29 |
| Phase | Phase 1 |
What the finished NCT06266572 record still lists
NCT06266572 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 1 intervention - of which Overcoming and Addressing Stigma in Substance Use Disorders (OASIS) is the first listed.
NCT06266572 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06266572 about?
NCT06266572 is a clinical study titled "Overcoming Stigma and Improving Outcomes for SUDs Through Education, Engagement, and Empowerment". C4 Innovations (C4) and partners at Yale University (Yale) and the West Haven VA Medical Center (WHVA) proposed to develop and test OASIS (Overcoming and Addressing Stigma in Substance Use Disorders), a web-based educational platform for primary care clinicians and individuals with Opioid Use Disord...
What is the current status of trial NCT06266572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2021-09-30. Estimated completion is 2023-09-29.
What interventions are being tested in trial NCT06266572?
The interventions under investigation include: Overcoming and Addressing Stigma in Substance Use Disorders (OASIS) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06266572?
This trial is sponsored by Center for Social Innovation, Massachusetts, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06266572's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI